Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 64 Future 3-5Y EPS without NRI Growth Rate is -41.40 as of Sep. 08, 2026. GuruFocus rates HMDCF with a GF Score™ of 64/100 and a GF Value™ of $2.07. The stock has 7 warning signs investors should review. Among 230 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 99.57% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, HUTCHMED (China)'s Future 3-5Y EPS without NRI Growth Rate is -41.40.
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
HUTCHMED (China) Future 3-5Y EPS without NRI Growth Rate Related Terms
HMDCF vs ZTS, UTHR: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) Future 3-5Y EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of -41.40 mean?
HUTCHMED (China) (HMDCF) has a Future 3-5Y EPS without NRI Growth Rate of -41.40 as of Sep. 08, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #229 out of 230 companies in the Drug Manufacturers industry, placing it in the top 99.6%.
Is HUTCHMED (China)'s Future 3-5Y EPS without NRI Growth Rate too high?
HUTCHMED (China)'s current Future 3-5Y EPS without NRI Growth Rate is -41.40. Based on the distribution chart, HUTCHMED (China) ranks #229 out of 230 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Future 3-5Y EPS without NRI Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #229 out of 230 companies for Future 3-5Y EPS without NRI Growth Rate. This places HUTCHMED (China) in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 16.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Drug Manufacturers company?
The median Future 3-5Y EPS without NRI Growth Rate among Drug Manufacturers companies is 16.67, based on 230 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median Future 3-5Y EPS without NRI Growth Rate is 16.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Future 3-5Y EPS without NRI Growth Rate is -41.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
HUTCHMED (China) (HMDCF) has a current Future 3-5Y EPS without NRI Growth Rate of -41.40. The stock's GF Value™ is $2.07, compared to a current price of $2.16 — trading 4.3% above its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is -41.40. HUTCHMED (China)'s overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current Future 3-5Y EPS without NRI Growth Rate is -41.40 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be overvalued.
The current stock price of $2.16 is trading 4.3% above its estimated GF Value™ of $2.07.
Key valuation signals for HMDCF:
Future 3-5Y EPS without NRI Growth Rate: -41.40
GF Value™: $2.07 vs. price of $2.16 (4.3% above fair value)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
64GF Score
Get the complete analysis for HMDCF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
